HHV HHV ‐6 in liver transplantation: A literature review

摘要

Abstract Human herpesvirus 6 ( HHV ‐6A and HHV ‐6B) can cause primary infection or reactivate from latency in liver transplant recipients, which can result in a variety of clinical syndromes, including fever, hepatitis, encephalitis and higher rates of graft dysfunction as well as indirect effects including increased risks of mortality, CMV disease, hepatitis C progression and greater fibrosis scores. Although HHV ‐6 infection is currently diagnosed by quantifying viral DNA in plasma or blood, biopsy to demonstrate histopathological effects of HHV ‐6 remains the gold standard for diagnosis of end‐organ disease. HHV ‐6 reactivation may be restricted to the infected organ with no evidence of active infection in the blood. HHV ‐6 infections in liver transplant patients are mostly asymptomatic, but clinically significant tissue‐invasive infections have been treated successfully with ganciclovir, foscarnet or cidofovir. Inherited chromosomally integrated HHV ‐6 (ci HHV ‐6), in either the recipient or the donor organ, may create confusion about systemic HHV ‐6 infection. Recipients with inherited ci HHV ‐6 may have an increased risk of opportunistic infection and graft rejection. This article reviews the current scientific data on the clinical effects, risk factors, pathogenesis, diagnosis and treatment of HHV ‐6 infections in liver transplant recipients.